Myeloma Crowd Radio

Myeloma Crowd Radio brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.

http://www.blogtalkradio.com/myelomacrowdradio

subscribe
share



 
 

      episode 5: Myeloma Crowd Radio: HealthTree With Rafael Fonseca, MD, Mayo Clinic


      A new tool for multiple myeloma patients is coming in June! Join us as we discuss the Myeloma Crowd's new initiative called HealthTree with Rafael Fonseca, MD of the Mayo Clinic in Scottsdale.  HealthTree will help myeloma patients understand their personally relevant treatment options, find clinical trials, track lab data and help accelerate research towards a cure.   Over 80% of myeloma patients are treated by general oncologists, yet data shows that patients who see myeloma specilists ca...


      share





         1h7m
       
       

      episode 4: Myeloma Crowd Radio: Luciano Costa, MD, PhD, University of Alabama


      Adequate treatment of multiple myeloma at diagnosis is a key issue for patients because their first remission is typically the longest and most durable. Dr. Luciano Costa of the University of Alabama joins Myeloma Crowd Radio to discuss a trial testing some of the best therapies for myeloma up-front: lenalidomide, dexamethasone, carfilzomib and daratumumab followed by a stem cell transplant. The same four drugs will be used after transplant as "consolidation" therapy. The goal is to ...


      share





       2018-04-16  1h0m
       
       

      episode 3: Myeloma Crowd Radio: Veronika Bachanova, MD, PhD, University of Minnesota


      Natural killer cells are the body's way of eliminating cancerous cells. When a myeloma patient's immune system is too weak, the natural killer cells can't effectively do their job to eliminate myeloma. A study is now being done to test donor natural killer cells in relapsed myeloma patients. The natural killer cells are collected and combined with IL-2 to help them grow and expand. Elotuzumab is used to help the NK cells migrate to the myeloma tumor and has anti-myeloma effect on its own. ...


      share





       2018-03-12  51m
       
       

      episode 2: Myeloma Crowd Radio: William Matsui, MD, Johns Hopkins University


      Allogeneic stem cell transplant was the first ever immunotherapy available for mulitple myeloma patients. Dr. Matsui shares how the Johns Hopkins allo transplant procedure has significantly improved safety concerns. His research is now focused on extending and deepening remissions with a new immunotherapy antibody given with transplant. Dr. Matsui will also share his latest research on precursor myeloma cells (called myeloma stem cells) and how they can be targeted before growing into full ...


      share





       2018-02-16  1h10m
       
       

      Myeloma Crowd Radio: Martin Kaiser, MD, The Institute of Cancer Research, UK


      Dr. Martin Kaiser joins Myeloma Crowd Radio to share more about the latest advances in myeloma treatment in the United Kingdom and how the use of myeloma genomic data with thousands of patients in the UK is furthering new insights in myeloma care.    Thanks to our episode sponsor, SparkCures. SparkCures provides an easy way to find and join multiple myeloma clinical trials. 


      share





       2018-02-11  39m
       
       

      episode 1: Myeloma Crowd Radio: Robert Orlowski, MD, PhD, MD Anderson Cancer Center


      The year 2018 promises to be an exciting one in multiple myeloma research. Learn what about key findings from the recent ASH conference in addition to what we can look forward to in the coming year. With the explosion of immunotherapy and combination approaches now in the clinic and in clinical trials,  the choices are greatly expanding for myeloma patients. Listen to myeloma expert Robert Z. Orlowski, MD, PhD of the MD Anderson Cancer Center as he reviews the up-and-coming choices for the ...


      share





       2018-01-05  1h4m
       
       

      episode 1: Myeloma Crowd Radio: Diahanna Valentine, Critical Care Financial Consulting


      Multiple myeloma treatment can cause "financial toxicity" for patients who are trying to pay for care that will give them optimal outcomes. Diahanna Valentine joins the Myeloma Crowd to discuss financial resources that are available to myeloma patients in this informative. show.  Diahanna is Owner and Founder of Critical Care Financial Consulting, LLC which takes a holistic approach to managing your finances in the face of a critical or chronic illness. She is an 18+ year Financial Advisor, ...


      share





       2017-10-17  1h3m
       
       

      Myeloma Crowd Radio: Irene Ghobrial, MD & Salomon Manier, MD, PhD, Dana Farber


      Myeloma patients can't wait until blood-based "liquid biopsies" replace the dreaded bone marrow biopsy. Painful and intrusive, the bone marrow biopsy is today's "standard" of myeloma testing to determine levels of myeloma disease burden in patients. These biopsies need to be performed at diagnosis, relapse and repeated every so often to determine response to treatment. Researchers at the Dana Farber Cancer Institute and the Harvard School of Medicine are creating a blood-based test that ...


      share





       2017-09-27  49m
       
       

      Myeloma Crowd Radio: Michael O'Dwyer, MD, National University of Ireland


      Sugar molecules could act as a smoke screen for multiple myeloma cells, essentially hiding them from the immune system.  The surface sugars, called sialic acids, can mark the cancer cells as “self” cells, giving the immune system the signal to ignore them.  Dr. Michael O'Dwyer is Director of the Blood Cancer Network Ireland and Professor of Hematology at the National University of Ireland Galway. Dr. O'Dwyer has expertise in the glycosylation process as it relates to multiple myeloma. The gl...


      share





       2017-08-25  1h7m
       
       

      Myeloma Crowd Radio: Sagar Lonial, MD, Winship Cancer Institute


      The recent meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA) occurred recently in May and June. There are a wealth of updates on up-and-coming therapies, use of combinations to improve outcomes, strategies to reduce side effects and much more from myeloma specialists across the world.  Dr. Sagar Lonial will join us to share an overview of the major themes in myeloma advances from his leading-edge perspective. Dr. Sagar Lonial is an ...


      share





       2017-07-19  1h5m